Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study.
Various forms of atherogenic modified low-density lipoprotein (LDL) including oxidized LDL and small, dense LDL have increased negative charge as compared to normal LDL. Charge-modified LDL (electronegative LDL) and normal LDL subfractions in plasma are analyzed by capillary isotachophoresis (cITP) as fast-migrating LDL (fLDL) and slow-migrating LDL (sLDL). We examined the effects of pravastatin and simvastatin on charge-based LDL subfractions as determined by cITP in patients with hypercholesterolemia. Patients (n=72) with CHD or CHD risk factors and elevated LDL cholesterol (LDL-C) levels were randomly assigned to receive pravastatin or simvastatin. After treatment with statins for 3 and 6 months, both cITP fLDL and sLDL were reduced (p<0.05) from the baseline, but the effects did not differ between treatment with pravastatin and simvastatin. At baseline and after treatment for 3 months, cITP sLDL was correlated with LDL-C, but fLDL was correlated with inflammatory markers, high-sensitive C-reactive protein and LDL-associated platelet-activating factor acetylhydrolase, and atherogenic lipoproteins, remnant-like particle cholesterol and small, dense LDL cholesterol. In conclusion, cITP fLDL was related to inflammatory markers and atherogenic lipoproteins and was reduced by treatment with statins. Charge-modified LDL subfraction could be a potential marker for atherosclerosis and a target for therapy.
Zhang
Bo
B
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan. bozhang@fukuoka-u.ac.jp
Miura
Shin-ichiro
S
Yanagi
Daizaburo
D
Noda
Keita
K
Nishikawa
Hiroaki
H
Matsunaga
Akira
A
Shirai
Kazuyuki
K
Iwata
Atsushi
A
Yoshinaga
Kazuhiko
K
Adachi
Hisashi
H
Imaizumi
Tsutomu
T
Saku
Keijiro
K
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism*; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use; D012307:Risk Factors; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000378:metabolism
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D014280:Triglycerides; D002097:C-Reactive Protein; D019821:Simvastatin; D017035:Pravastatin